• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Absci Corporation (Amendment)

    2/14/24 9:42:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email
    SC 13G/A 1 d780767dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    Absci Corporation

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    00091E109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 00091E109       Page 2 of 6 Pages

     

     1   

     NAME OF REPORTING PERSONS

     

     Phoenix Venture Partners II, LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     14,379,522

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     14,379,522

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     14,379,522

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     15.5%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     PN

     


    CUSIP No. 00091E109       Page 3 of 6 Pages

     

     1   

     NAME OF REPORTING PERSONS

     

     Phoenix General Partner II LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     14,379,5221

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     14,379,522

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     14,379,522

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     15.5%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     OO

     

     

    1 

    Shares reported in this table are held by Phoenix Venture Partners II, LP, of which the Reporting Person is the sole general partner.


    CUSIP No. 00091E109       Page 4 of 6 Pages

     

    ITEM 1 (a).

    NAME OF ISSUER

    Absci Corporation (the “Issuer”)

     

    ITEM 1 (b).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    18105 SE Mill Plain Blvd

    Vancouver, WA 98683

     

    ITEM 2 (a).

    NAME OF PERSONS FILING

    This joint statement on Schedule 13G is being filed by Phoenix General Partner II LLC, a Delaware limited liability company (the “General Partner”), and Phoenix Venture Partners II, LP, a Delaware limited partnership (the “Fund” and, together with the General Partner, the “Reporting Persons”).

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to this Schedule 13G, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    ITEM 2 (b).

    ADDRESS OF PRINCIPAL BUSINESS OFFICE

    The business address of each of the Reporting Persons is 1700 El Camino Real, Suite 355, San Mateo, CA 94402.

     

    ITEM 2 (c).

    CITIZENSHIP

    The Fund is a Delaware limited partnership; and the General Partner is a Delaware limited liability company.

     

    ITEM 2 (d).

    TITLE OF CLASS OF SECURITIES

    Common stock, par value $0.0001 per share (the “Common Stock”).

     

    ITEM 2 (e).

    CUSIP NUMBER

    00091E109

     

    ITEM 3.

    Not Applicable.

     

    ITEM 4.

    OWNERSHIP

     

      (a)

    Amount beneficially owned by each Reporting Person: 14,379,522 shares of Common Stock.

     

      (b)

    Percent of class beneficially owned by each Reporting Person: 15.5%.

     

      (c)

    Number of shares as to which each of the Fund and the General Partner has (i) the sole power to vote or direct the vote of: 14,379,522, (ii) the shared power to vote or to direct the vote of: 0, (iii) the sole power to dispose or to direct the disposal of: 14,379,522, and (iv) the shared power to dispose or to direct the disposal of: 0.


    CUSIP No. 00091E109       Page 5 of 6 Pages

     

    The percentages of beneficial ownership reported herein, and on each Reporting Person’s cover page to this Schedule 13G, are based on a total of 92,938,477 shares of Common Stock issued and outstanding as of October 31, 2023, as reported in the most recent quarterly report of the Issuer on Form 10-Q for its fiscal quarter ended September 30, 2023.

     

    ITEM 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

    Not applicable.

     

    ITEM 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

    Not applicable.

     

    ITEM 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

    Not applicable.

     

    ITEM 9.

    NOTICE OF DISSOLUTION OF GROUP

    Not applicable.

     

    ITEM 10.

    CERTIFICATION

    Not applicable.


    CUSIP No. 00091E109       Page 6 of 6 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DATE: February 14, 2024
    PHOENIX VENTURE PARTNERS II, LP
    By:   Phoenix General Partner II LLC,
      its General Partner
    By:   /s/ John Chen
      John Chen
      Managing Member
    PHOENIX GENERAL PARTNER II LLC
    By:   /s/ John Chen
      John Chen
      Managing Member
    Get the next $ABSI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    7/3/2025$7.00Overweight
    Morgan Stanley
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    5/4/2023$4.00Buy
    H.C. Wainwright
    8/12/2022Overweight → Underweight
    JP Morgan
    More analyst ratings

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas bought $152,000 worth of shares (50,000 units at $3.04), increasing direct ownership by 18% to 327,264 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    7/29/25 8:37:44 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Redmile Group, Llc bought $999,999 worth of shares (222,222 units at $4.50) (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/5/24 9:30:43 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Absci to Participate in Upcoming Investor Conferences

    VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences: 2025 Wells Fargo Healthcare Conference (Boston, MA) Hosting 1x1 meetings on Wednesday, September 3 Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) Fireside chat on Monday, September 8 at 3:20 p.m. Eastern Time / 12:20 p.m. Pacific Time, and hosting 1x1 meetings H.C. Wainwright 27th Annual Global Investment Conference (New York, NY) Fireside chat on Tuesday, Se

    8/20/25 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results

    Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of 2028 Expanded ongoing collaboration with Almirall, with election of a second target focused on dermatological indications VANCOUVER, Wash. and NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operating results for the quarter ended June 30, 2025. "The past few months have been a period of strong execution for Absci, and we are positione

    8/12/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

    Almirall selects second target in AI Drug Creation collaborationExpanded collaboration builds on Absci's successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications. The expansion

    8/7/25 2:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas bought $152,000 worth of shares (50,000 units at $3.04), increasing direct ownership by 18% to 327,264 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    7/29/25 8:37:44 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Szela Mary T

    4 - Absci Corp (0001672688) (Issuer)

    7/9/25 4:46:43 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Szela Mary T

    3 - Absci Corp (0001672688) (Issuer)

    7/9/25 4:43:26 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    SEC Filings

    View All

    SEC Form 424B3 filed by Absci Corporation

    424B3 - Absci Corp (0001672688) (Filer)

    8/22/25 4:39:43 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: Absci Corporation filed SEC Form 8-K: Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

    8-K/A - Absci Corp (0001672688) (Filer)

    8/12/25 5:10:10 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-3 filed by Absci Corporation

    S-3 - Absci Corp (0001672688) (Filer)

    8/12/25 5:06:47 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Absci Corporation with a new price target

    Morgan Stanley resumed coverage of Absci Corporation with a rating of Overweight and set a new price target of $7.00

    7/3/25 7:48:59 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Needham initiated coverage on Absci Corporation with a new price target

    Needham initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00

    1/22/25 7:30:02 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Guggenheim initiated coverage on Absci Corporation with a new price target

    Guggenheim initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $10.00

    10/2/24 7:13:36 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    View All

    Absci Appoints Biopharma Leader Mary Szela to Board of Directors

    VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of veteran biopharmaceutical executive Mary Szela to its Board of Directors. With decades of R&D and commercial leadership experience, Ms. Szela has played pivotal roles in advancing transformative therapies, notably guiding the global launch and expansion of Humira® into multiple indications during her tenure at Abbott Laboratories. "Mary has been a driving force behind the development of one of the most successful therapies in the industry, bringing a rare and invaluable bread

    7/7/25 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

    Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.  In addition to joining Absci's Board, Sir Pangalos will co-chair Absci's Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas "Mene" Pangalos to its Board of Directors and as co-chair of Absci's Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca. He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets. "The rapid e

    1/10/24 7:30:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips

    VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his exceptional leadership experience and deep industry knowledge in the healthcare and technology industries, van Houten will play a pivotal role in supporting Absci's strategic vision and growth trajectory. Frans van Houten is a highly regarded business executive with a remarkable track record of success. During his tenure as CEO of Royal Philips, van Houten led the company's transformation into a global leader in health technology, overseeing a critical strategic transformation, resulting in a

    6/6/23 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Financials

    Live finance-specific insights

    View All

    Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

    VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will report business updates and financial and operating results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The we

    7/30/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

    Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the qu

    5/13/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025

    VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after th

    4/14/25 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Absci Corporation

    SC 13G - Absci Corp (0001672688) (Subject)

    11/14/24 4:02:50 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Absci Corporation

    SC 13G/A - Absci Corp (0001672688) (Subject)

    11/12/24 9:50:12 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Absci Corporation (Amendment)

    SC 13D/A - Absci Corp (0001672688) (Subject)

    3/5/24 5:15:30 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care